Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5.2% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price traded up 5.2% during mid-day trading on Tuesday . The company traded as high as $87.53 and last traded at $87.9450. 217,736 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 892,121 shares. The stock had previously closed at $83.60.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. William Blair reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Wedbush lifted their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. HC Wainwright lifted their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $120.00 price target on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $117.82.

Dianthus Therapeutics Stock Up 1.0%

The company has a market cap of $4.90 billion, a price-to-earnings ratio of -21.70 and a beta of 1.18. The firm has a 50-day simple moving average of $85.74 and a 200 day simple moving average of $59.61.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 323,021 shares of company stock valued at $26,564,008. Company insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Fairmount Funds Management LLC increased its holdings in shares of Dianthus Therapeutics by 22.2% in the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after purchasing an additional 600,000 shares during the period. Vestal Point Capital LP increased its stake in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the period. Wellington Management Group LLP increased its stake in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the period. Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after acquiring an additional 406,254 shares during the period. Finally, TCG Crossover Management LLC increased its stake in shares of Dianthus Therapeutics by 11.7% during the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after acquiring an additional 175,000 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.